Abstract
The objective of most phase III, randomized controlled clinical trials with antimicrobials is to obtain approval by the regulatory agencies for a specific indication. However, the real clinical utility of these trials is limited because the patients included are usually at low risk of infection caused by antibiotic-resistant or difficult-to-treat microorganisms, and the conditions in which the studies are performed differ from those in real life. Therefore, observational studies are an essential complement. Once a new antibiotic has been commercialized, the post-registry follow-up phase begins. The EUCORE registry is a European multicenter, retrospective, non-comparative post-authorization study that included patients receiving at least one dose of daptomycin. Despite their limitations, these types of study provide useful information that should be thoroughly analyzed and interpreted.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have